Isoform-selective histone deacetylase inhibitors: the trend and promise of disease treatment

References

• Tan J , CangS , MaY , PetrilloRL , LiuD . Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents . J. Hematol. Oncol.3 , 5 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Thaler F , MercurioC . Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next . ChemMedChem9 ( 3 ), 523 – 526 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gupta P , ReidRC , IyerA , SweetMJ , FairlieDP . Towards isozyme-selective HDAC inhibitors for interrogating disease . Curr. Top. Med. Chem.12 ( 14 ), 1479 – 1499 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Montgomery RL , HsiehJ , BarbosaAC , RichardsonJA , OlsonEN . Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development . Proc. Natl Acad. Sci. USA106 ( 19 ), 7876 – 7881 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ye F , ChenY , HoangTet al. HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction . Nat. Neurosci.12 ( 7 ), 829 – 838 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Chen Y , WangH , YoonSOet al. HDAC-mediated deacetylation of NF-κB is critical for Schwann cell myelination . Nat. Neurosci.14 ( 4 ), 437 – 441 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Jacob C , ChristenCN , PereiraJAet al. HDAC1 and HDAC2 control the transcriptional program of myelination and the survival of Schwann cells . Nat. Neurosci.14 ( 4 ), 429 – 436 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Chen S , BellewC , YaoXet al. Histone deacetylase (HDAC) activity is critical for embryonic kidney gene expression, growth, and differentiation . J. Biol. Chem.286 ( 37 ), 32775 – 32789 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Montgomery RL , DavisCA , PotthoffMJet al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility . Genes Dev.21 ( 14 ), 1790 – 1802 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• LeBoeuf M , TerrellA , TrivediSet al. Hdac1 and Hdac2 act redundantly to control p63 and p53 functions in epidermal progenitor cells . Dev. Cell19 ( 6 ), 807 – 818 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Yamaguchi T , CubizollesF , ZhangYet al. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression . Dev. Cell24 ( 5 ), 455 – 469 ( 2010 ).
   Google Scholar
• Dovey OM , FosterCT , ConteNet al. Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice . Blood121 ( 8 ), 1335 – 1344 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Wilting RH , YanoverE , HeidemanMRet al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis . EMBO J.29 ( 15 ), 2586 – 2597 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Ma P , PanH , MontgomeryRL , OlsonEN , SchultzRM . Compensatory functions of histone deacetylase 1 (HDAC1) and HDAC2 regulate transcription and apoptosis during mouse oocyte development . Proc. Natl Acad. Sci. USA109 ( 8 ), e481 – e489 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Li X , InksES , LiXet al. Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity . J. Med. Chem.57 ( 8 ), 3324 – 3341 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Distillery: Therapeutics – Cancer . SciBX7 ( 18 ), doi:10.1038/scibx.2014.519 ( 2014 ).
   Google Scholar
• https://globalmedicaldiscovery.com/key-drug-discovery-articles/discovery-first-n-hydroxycinnamamide-based-histone-deacetylase-13-dual-inhibitors-potent-oralantitumor-activity/ . Global medical discovery .
   Google Scholar
• Thomas EA . Involvement of HDAC1 and HDAC3 in the pathology of polyglutamine disorders: therapeutic implications for selective HDAC1/HDAC3 inhibitors . Pharmaceuticals7 ( 6 ), 634 – 661 ( 2014 ).
   Google Scholar
• Sangshetti JN , SakleNS , DehghanMH , ShindeDB . Histone deacetylases as targets for multiple diseases . Mini Rev. Med. Chem.13 ( 7 ), 1005 – 1026 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Fessler EB , ChibaneFL , WangZ , ChuangDM . Potential roles of HDAC inhibitors in mitigating ischemia-induced brain damage and facilitating endogenous regeneration and recovery . Curr. Pharm. Des.19 ( 28 ), 5105 – 5120 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Weïwer M , LewisMC , WagnerFF , HolsonEB . Therapeutic potential of isoform-selective HDAC inhibitors for the treatment of schizophrenia . Future Med. Chem.5 ( 13 ), 1491 – 1508 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Garbes L , RiesslandM , WirthB . Histone acetylation as a potential therapeutic target in motor neuron degenerative diseases . Curr. Pharm. Des.19 ( 28 ), 5093 – 5104 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kazantsev AG , ThompsonLM . Therapeutic application of histone deacetylase inhibitors for central nervous system disorders . Nat. Rev. Drug Discov.7 ( 10 ), 854 – 868 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Blanchard F , ChipoyC . Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?Drug Discov. Today10 ( 3 ), 197 – 204 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Andrews KT , TranTN , FairlieDP . Towards histone deacetylase inhibitors as new antimalarial drugs . Curr. Pharm. Des.18 ( 24 ), 3467 – 3479 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Pierce RJ , Dubois-AbdesselemF , LancelotJ , AndradeL , OliveiraG . Targeting schistosome histone modifying enzymes for drug development . Curr. Pharm. Des.18 ( 24 ), 3567 – 3578 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Colussi C , IlliB , RosatiJet al. Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment . Pharmacol. Res.62 ( 1 ), 3 – 10 ( 2010 ).
   PubMed Web of Science ®Google Scholar